Resona Asset Management Co. Ltd. Buys Shares of 2,917 Krystal Biotech, Inc. $KRYS

Resona Asset Management Co. Ltd. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,917 shares of the company’s stock, valued at approximately $401,000.

Other hedge funds also recently made changes to their positions in the company. State of New Jersey Common Pension Fund D lifted its stake in Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock valued at $2,066,000 after purchasing an additional 4,682 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Krystal Biotech during the first quarter worth $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after buying an additional 365,304 shares in the last quarter. S Squared Technology LLC lifted its stake in shares of Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock valued at $17,528,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at $327,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Bank of America upped their target price on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Chardan Capital upped their price objective on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. Citigroup lifted their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $203.00 on Wednesday. The stock has a market capitalization of $5.89 billion, a PE ratio of 30.43 and a beta of 0.65. The business’s 50 day simple moving average is $176.67 and its 200 day simple moving average is $154.33. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $212.98.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. As a group, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).